v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Total RadNet, Inc.'s Equity
Common Stock
Common Stock
Equity Incentive Plan
Common Stock
DeepHealth, Inc.
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2024     74,036,993            
Beginning balance at Dec. 31, 2024 $ 1,133,410 $ 902,308 $ 7     $ 988,147 $ (9,061) $ (76,785) $ 231,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     62,296            
Issuance of common stock upon exercise of options 555 555 $ 1     554      
Issuance of common stock under the equity compensation plan (in shares)       970,712 3,438        
Stock-based compensation expense 37,275 37,275       37,275      
Forfeiture of restricted stock and share cancellation (in shares)     (6,337)            
Forfeiture of restricted stock and share cancellation (40) (40)       (40)      
Distributions paid to noncontrolling interests (3,313)               (3,313)
Contribution from noncontrolling partner 2,389               2,389
Change in cumulative foreign currency translation adjustment 13,632 13,632         13,632    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 2,056 2,056         2,056    
Net (loss) income (6,703) (23,472)           (23,472) 16,769
Ending balance (in shares) at Jun. 30, 2025     75,067,102            
Ending balance at Jun. 30, 2025 1,179,261 932,314 $ 8     1,025,936 6,627 (100,257) 246,947
Beginning balance (in shares) at Mar. 31, 2025     74,956,566            
Beginning balance at Mar. 31, 2025 1,136,517 898,139 $ 7     1,016,762 (3,919) (114,711) 238,378
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     50,340            
Issuance of common stock upon exercise of options 434 434       433      
Issuance of common stock under the equity compensation plan (in shares)       63,877          
Stock-based compensation expense 8,761 8,761       8,761      
Forfeiture of restricted stock and share cancellation (in shares)     (3,681)            
Forfeiture of restricted stock and share cancellation (20) (20)       (20)      
Distributions paid to noncontrolling interests (2,400)               (2,400)
Contribution from noncontrolling partner 2,389               2,389
Change in cumulative foreign currency translation adjustment 9,523 9,523         9,523    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 1,023 1,023         1,023    
Net (loss) income 23,034 14,454           14,454 8,580
Ending balance (in shares) at Jun. 30, 2025     75,067,102            
Ending balance at Jun. 30, 2025 $ 1,179,261 932,314 $ 8     1,025,936 6,627 (100,257) 246,947
Beginning balance (in shares) at Dec. 31, 2025 77,399,615   77,399,615            
Beginning balance at Dec. 31, 2025 $ 1,355,886 1,089,890 $ 8     1,180,434 4,885 (95,437) 265,996
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     95,672            
Issuance of common stock upon exercise of options 612 612 $ 0     612      
Issuance of common stock under the equity compensation plan (in shares)       979,451          
Stock-based compensation expense 41,998 41,998       41,998      
Forfeiture of restricted stock and share cancellation (in shares)     (18,857)            
Forfeiture of restricted stock and share cancellation (83) (83)       (83)      
Purchase of noncontrolling interests (3,927)               (3,927)
Issuance of common stock in connection with acquisitions (in shares)     190,924            
Issuance of common stock in connection with acquisitions 0 0       0      
Change in cumulative foreign currency translation adjustment (10,550) (10,389)         (10,389)   (161)
Noncontrolling interest recognized in business combination 14,593               14,593
Net (loss) income $ (4,478) (25,936)           (25,936) 21,458
Ending balance (in shares) at Jun. 30, 2026 78,646,805   78,646,805            
Ending balance at Jun. 30, 2026 $ 1,394,051 1,096,092 $ 8     1,222,961 (5,504) (121,373) 297,959
Beginning balance (in shares) at Mar. 31, 2026     78,545,837            
Beginning balance at Mar. 31, 2026 1,352,712 1,080,551 $ 8     1,211,912 (2,466) (128,903) 272,161
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     28,560            
Issuance of common stock upon exercise of options 509 509 $ 1     509      
Issuance of common stock under the equity compensation plan (in shares)       86,491          
Stock-based compensation expense 10,558 10,558       10,558      
Forfeiture of restricted stock and share cancellation (in shares)     (14,083)            
Forfeiture of restricted stock and share cancellation (18) (18)       (18)      
Distributions paid to noncontrolling interests (1,525)               (1,525)
Change in cumulative foreign currency translation adjustment (3,032) (3,038)         (3,038)   6
Noncontrolling interest recognized in business combination 14,593               14,593
Net (loss) income $ 20,254 7,530           7,530 12,724
Ending balance (in shares) at Jun. 30, 2026 78,646,805   78,646,805            
Ending balance at Jun. 30, 2026 $ 1,394,051 $ 1,096,092 $ 8     $ 1,222,961 $ (5,504) $ (121,373) $ 297,959